# Safety and Tolerability of Lu AF95245 in Healthy Young Men

> **NCT04199585** · PHASE1 · TERMINATED · sponsor: **H. Lundbeck A/S** · enrollment: 18 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Lu AF95245
- **DRUG:** Lu AF95245 14C radiolabelled spiked dosage
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04199585
- **Lead sponsor:** H. Lundbeck A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-12-10
- **Primary completion:** 2020-02-16
- **Final completion:** 2020-02-19
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** new safety data from another study
- **Last updated:** 2020-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04199585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04199585, "Safety and Tolerability of Lu AF95245 in Healthy Young Men". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04199585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*